Cardiology panels
From evidence to practice: Narrowing the gap
Dr Keith Fox talks to Drs Gregg Stone and Robert Harrington about why it takes so long for new evidence-based therapies to be adopted in clinical practice, the importance of national registries, and what can be done to make treatment guidelines more useful.
Genetic beta-blockade
What are the implications of an exciting discovery of intrinsic genetic beta-blockade common to 40% of people of African ancestry?

Dr Eric Topol invites you to share your opinions.

Click here to view the video blog and join the discussion.

HeartWire clips
On moving to industry: Interview with Dr Terry Ferguson
In conversation with heartwire news and features editor Larry Husten, Dr Terry Ferguson muses on changes to daily life, decision making processes, and patient care from a different perspective resulting from his new position in industry.
The Cardiology Show
Surrogate end points on trial: ENHANCE and other controversies
Part 2 is now live!
Nine of the world's top cardiologists gathered in Chicago to take on the issues raised by data released at the American College of Cardiology Scientific Sessions.

Dr Valentin Fuster moderates this frank and sometimes heated discussion on the results of ENHANCE, STRADIVARIUS, ONTARGET, and PERISCOPE, and the questions they raise about the responsibility of industry and the relevance of surrogate end points.
Forum
Smoking ban?
Read about our forum moderator's heroic and sometimes comic efforts to get a smoking ban passed by her city council in tobacco country.
Thumbs up, thumbs down
Controversies: ENHANCE and ACCORD
Clinical trials are under attack and in the headlines. What is the proper role of the investigators? What are the responsibilities of industry? Join Drs Eric J Topol and Robert M Califf in a discussion of the many issues surrounding ENHANCE and ACCORD.
Question
Is insufficient disclosure of conflicts of interest a bigger problem in the cardiac device literature than it is in that of cardiac drugs?”
(See:Both researchers and journals are to blame for inconsistent disclosure of conflicts of interest)
Yes
No
Vote








Renin-angiotensin system: A new target for treating obesity and insulin resistance?
The finding raises the possibility that drugs that interfere with the renin-angiotensin system may have benefits beyond blood-pressure lowering. (Jayasooriya AP et al. Proc Natl Acad Sci; published online before print April 28, 2009.)
To view the full text of this article, you must be logged in as a registered member.

Members
Login Now 		Not a member
Free registration
Username
Password
Forgot your password?
 
Remember me